Topic: chronic hepatitis B
The deal, which will see Roche and Dicerna collaborate on other hepatitis B virus assets, is worth up to $1.5 billion in milestones.
The deal comes shortly after GlaxoSmithKline achieved clinical proof of concept for the Ionis-partnered hepatitis B program.
Arrowhead Pharmaceuticals will assess ARO-HBV in combination with two undisclosed drugs selected by Johnson & Johnson.
Vir Biotechnology has started trials of its gene-silencing drug for hepatitis B, the first candidate from its partnership with Alnylam Pharmaceuticals.
After a string of pipeline failures, Vical has called in advisers to help decide the future of the company.
Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.
The seroclearance gives a boost to Arrowhead as it plots a path back from safety concerns that derailed ARC-520 in 2016.
Vivek Ramaswamy’s Roivant has just put another sizable block of cash behind a hepatitis B program in development at Canada’s Arbutus Biopharma.
GeoVax has partnered with Georgia State University to try to pursue an elusive goal—the development of an effective therapeutic vaccine for hepatitis B virus (HBV) infections.